Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

LYEL

NASDAQ

Lyell Immunopharma (LYEL)

14.38 USD +0.14% vs prior close Sep 4, 2026
Lyell Immunopharma, Inc. price graph
10 sessions
15.5 14.0 24 Aug 4 Sep

The line runs 14.69 USD on 24 August through 14.38 USD on 4 September, on a scale from 14.0 to 15.5. Days the market did not trade hold the previous close, flat.

Market cap
353.5M USD
Revenue, year to Dec 2025
36K USD
EPS, diluted, year to Dec 2025
−16.06 USD
52-week range
11 USD – 38.55 USD
Avg volume
14.7K

as of Sep 4, 2026

Have Lyell Immunopharma (LYEL) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Lyell Immunopharma insiders reported 6 open-market sales and 2 purchases (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 10 Nov 2026

2buys
6sells
$49.97Mnet bought
0other filings
Have Lyell Immunopharma (LYEL) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Nov 2026Bulis Veronica SanchezVP, Corporate ControllerSell4167K USD
10 Nov 2026Hill Stephen J.Chief Operating OfficerSell881K USD
10 Nov 2026Lee Gary K.Chief Scientific OfficerSell1292K USD
10 Nov 2026Seely LynnPresident and CEOSell5459K USD
04 Nov 2026ARCH Venture Partners IX, LLC10% OwnerBuy2,321,26225.0M USD
04 Nov 2026ARCH Venture Fund XIII, L.P.10% OwnerBuy2,321,26225.0M USD
12 Oct 2026Aguirre Jarrad MattieuChief Medical OfficerSell4224K USD
10 Sep 2026Shook DavidChief Medical OfficerSell5006K USD
Bought2 open-market purchases4,642,524$50.00M
Sold6 open-market sales2,100$29K

Which funds hold Lyell Immunopharma (LYEL)?

7 of the 45 institutional funds we track reported a Lyell Immunopharma position for the quarter ended 30 Sep 2026 — a combined 10.1M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Lyell Immunopharma (LYEL)?
FundPositionSharesValueShares q/q
AQR Capital ManagementNew position345,9223.4M USD
Renaissance TechnologiesAdded189,1221.9M USD+45.3%
Two Sigma InvestmentsAdded168,1221.6M USD+217.6%
Millennium ManagementTrimmed141,0591.4M USD−61.6%
Citadel AdvisorsAdded106,7441.0M USD+471.0%
Point72 Asset ManagementAdded56,992558K USD+118.5%
Marshall WaceTrimmed18,746184K USD−82.4%

What has been filed or recorded for Lyell Immunopharma (LYEL)?

The filings we hold for Lyell Immunopharma, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Lyell Immunopharma (LYEL)?
And
30 Oct 2026Fails to deliverShares failed to deliver140 shares2K USD notional · 0.001% of shares out
29 Oct 2026Fails to deliverShares failed to deliver81 shares885 USD notional · <0.001% of shares out
28 Oct 2026Fails to deliverShares failed to deliver18 shares182 USD notional · <0.001% of shares out
15 Oct 2026Fails to deliverShares failed to deliver1,399 shares11K USD notional · 0.006% of shares out
13 Oct 2026Fails to deliverShares failed to deliver80 shares662 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.86 USDRevenue $0M
30 Sep 2026FinancialsTotal assets273.9M USDat period end
30 Sep 2026FinancialsTotal equity192.7M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.92 USDRevenue $0M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.10 USDRevenue $0M
31 Dec 2025Annual reportFY 2025 reportedEPS −16.06 USDRevenue $0M
31 Dec 2025FinancialsRevenue36K USDfiscal year
31 Dec 2025FinancialsNet income−274.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−16.06 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −2.13 USDRevenue $0M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −2.89 USDRevenue $0M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −3.54 USDRevenue $0M
31 Dec 2024Annual reportFY 2024 reportedEPS −26.23 USDRevenue $0M

What do people ask about Lyell Immunopharma (LYEL)?

From live data
What did Lyell Immunopharma shares close at?14.38

Lyell Immunopharma closed at 14.38 USD on 4 Sep 2026, up 0.14% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Lyell Immunopharma’s market cap?353.5M

Lyell Immunopharma is worth 353.5M USD by market value as of 4 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Lyell Immunopharma’s revenue?36K

Lyell Immunopharma reported revenue of 36K USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Lyell Immunopharma insiders bought or sold shares recently?6 sales

In the 90 days to 22 Nov 2026, Lyell Immunopharma insiders reported 6 open-market sales and 2 purchases (SEC Form 4). See Insiders

Which funds own Lyell Immunopharma?7 of 45

7 of the 45 funds we track reported a Lyell Immunopharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Two Sigma Investments. See Funds

When did Lyell Immunopharma last report earnings?−1.86

Lyell Immunopharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.86 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words